Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 09, 2015 09:05 ET | Source: Advaxis

Advaxis to Present Poster on ADXS-HER2 at SABCS 2015

PRINCETON, N.J., Dec. 09, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced that it will present a poster on...
December 01, 2015 09:05 ET | Source: Advaxis

Advaxis Receives Orphan Drug Designation in the European Union for ADXS-HER2 for the Treatment of Osteosarcoma

PRINCETON, N.J., Dec. 01, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced that the European Medicines...
November 17, 2015 09:05 ET | Source: Advaxis

Advaxis to Receive $1.6 Million Through New Jersey Technology Business Tax (NOL) Program

PRINCETON, N.J., Nov. 17, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced the Company has received...
November 09, 2015 09:05 ET | Source: Advaxis

Advaxis Presents New Data Featuring Its Lm Technology™ at the Society for Immunotherapy of Cancer 2015 Annual Meeting

High-dose axalimogene filolisbac immunotherapy will advance to expansion phase PRINCETON, N.J., Nov. 09, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology...
November 05, 2015 09:05 ET | Source: Advaxis

Advaxis to Present at the Jefferies Autumn 2015 Global Healthcare Conference

PRINCETON, N.J., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the Company will...
November 02, 2015 16:05 ET | Source: Advaxis

Advaxis Provides Additional Information on Clinical Hold

PRINCETON, N.J., Nov. 02, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today provided additional information...
October 27, 2015 09:03 ET | Source: Advaxis

Advaxis Launches MINE(TM) Collaboration

PRINCETON, N.J., Oct. 27, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced the launch of a research...
October 13, 2015 09:05 ET | Source: Advaxis

Advaxis’s Cancer Immunotherapies to be Featured in Three Poster Presentations at the 2015 SITC Annual Meeting

PRINCETON, N.J., Oct. 13, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that three abstracts...
October 06, 2015 16:01 ET | Source: Advaxis

Advaxis Reports Clinical Hold of Investigational Agent Axalimogene Filolisbac

Advaxis Expects That This Clinical Hold Will Be Resolved Expeditiously and Without Significant Interruption to the HPV Clinical Development Program Conference Call Today, October 6, at 4:30...
September 28, 2015 09:05 ET | Source: Advaxis

First Human Patient Treated in Phase 1b Study of Advaxis's ADXS-HER2 in HER2 Expressing Solid Tumors

Dose escalation portion of study will investigate safety and tolerability of ADXS-HER2 as monotherapy Maximum tolerated dose may translate into pivotal trial in pediatric osteosarcoma PRINCETON,...